Research progress on the role of DDR1 in cancer and targeted therapy strategy

Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by various types of collagen.Abnormal activation of DDR1 is closely related to the occurrence and development of solid tumors and plays an important role in the regulation of cell adhesion, survival, proliferation, migration, and invasion.Thus, DDR1 is a promising therapeutic target in the field of oncology.This review introduces the structural characteristics of DDR1, focusing on its role in tumor progression and related signaling pathways.It also explores the relationship between DDR1 and tumor chemotherapy resistance, and elaborates on the current research status and development prospects for inhibitors and antibodies targeting DDR1.Thus, the DDR1 inhibition strategy may serve as a new alternative for treating cancer patients. Key words: DDR1; cancer progression; targeted therapy; selective inhibitorsDiscoidin domain receptors (DDRs) were discovered in the slime mold, Dictyostelium discodium in the early 1990s [1].DDRs activation is triggered by various forms of collagen.DDR1 plays a vital role in the progression of cancer, participating in regulating multiple cellular processes such as tumor cell proliferation, migration, metabolism, epithelial-mesenchymal transition (EMT), and matrix remodeling, ultimately affecting the survival of patients with cancer.In recent years, various small-molecule tyrosine kinase inhibitors targeting DDR1 have been developed.